FOI 5165 – Feedback On Insulin Pump Program

Written by Claude Haiku 4.5 from the extracted text on 16 May 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

Royal Hobart Hospital's Paediatric Diabetes Centre provided feedback on the JDRF insulin pump program restructure, documenting clinical concerns about limiting funding to a single pump model. The facility reported that 21% of their insulin pump users were JDRF-funded, projected to rise to 37% under new funding rounds. They advocated for multiple hybrid closed-loop pump options, noting the mylife YpsoPump with CamAPS FX algorithm requires higher user engagement and technical literacy than alternatives like Medtronic 780G and Tandem t:slim. The centre raised practical barriers including Android-only smartphone dependency, associated data costs for low-income families, and lack of real-time monitoring for Apple device users. They recommended that if the YpsoPump remained the sole JDRF option, ongoing smartphone replacement and mobile data provision should be included throughout the four-year warranty period to ensure equitable access and optimal clinical outcomes across diverse patient populations.